Obesity as a Disease of Visceral Adipose Tissue: MMP Activation and AGE Accumulation as Key Mechanisms of Metabolic Complications
Authors:
- Konrad WiśniewskiKWKonrad Wiśniewski
- Barbara ChoromańskaBCBarbara Choromańska
- Mateusz MaciejczykMateusz Maciejczyk
- Alan TkaczukATAlan Tkaczuk
- Andrzej KupiszAKAndrzej Kupisz
- Roman CemagaRCRoman Cemaga
- Jacek DadanJDJacek Dadan
- Małgorzata Żendzian-PiotrowskaMŻMałgorzata Żendzian-Piotrowska
- Anna ZalewskaAnna Zalewska
- Piotr Andrzej MyśliwiecPiotr Andrzej Myśliwiec
Preprint
- 3 December 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Obesity is increasingly recognized as a chronic molecular disease of visceral adipose tissue rather than a simple excess of body weight. Structural remodeling and biochemical damage within adipose depots — particularly extracellular matrix (ECM) degradation and oxidative protein modification — are believed to play a central role in the development of metabolic complications. This study evaluated matrix metalloproteinase (MMP) activity and protein glycooxidation in visceral and subcutaneous adipose tissue, as well as plasma in individuals with obesity. Using a fluorescence resonance energy transfer (FRET)–based assay and fluorimetric quantification of advanced glycation end-products (AGEs), we demonstrated markedly increased activity of all analyzed MMPs (MMP-1, -2, -7, -9, -11, -13) and significantly higher accumulation of selected AGE-related structures (dityrosine (DT), amyloid cross-β-structure, vesperlysine (VES) , pentosidine (PEN)) in visceral adipose tissue of obese patients. These findings indicate that visceral adipose tissue forms a localized inflammatory–proteolytic microenvironment rather than a reflection of systemic circulating pathology. The coexistence of ECM degradation and glycooxidation may mechanistically promote insulin resistance and cardiometabolic risk. These findings suggest that clinical assessment of obesity may require more than anthropometric parameters and circulating biomarkers. Molecular profiling of visceral adipose tissue — directly or via future non-invasive surrogate markers — could improve patient stratification, support personalized metabolic risk prediction and optimize therapeutic decision-making.Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- In vitro and in silico studies and a systematic literature review of antiglycation properties of amlodipineScientific Reports, 2025
- Inhibition of protein glycation by vasodilatory β-blockers – In vitro studies and in silico analysesBiomedicine & Pharmacotherapy, 2025
- Obesity Management in AdultsJAMA, 2023
- Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical ObesityThe Lancet Diabetes & Endocrinology, 2023
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Pro-inflammatory cytokines: The link between obesity and osteoarthritisCytokine & Growth Factor Reviews, 2018
- Cleavage of the leptin receptor by matrix metalloproteinase–2 promotes leptin resistance and obesity in miceScience Translational Medicine, 2018
- Early reduction of matrix metalloproteinase-8 serum levels is associated with leptin drop and predicts diabetes remission after bariatric surgeryInternational Journal of Cardiology, 2017
- Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetesPathologie Biologie, 2006
- Monitoring Metalloproteinase Activity Using Synthetic Fluorogenic SubstratesCurrent Protocols in Protein Science, 2003